Giampaolo Merlini, Pavia, Italy
Stefan Schönland, Heidelberg, Germany
Vaishali Sanchorawala, Boston, MA, USA
Arnaud Jaccard, Limoges, France
Bouke Hazenberg, Groningen, The Netherlands
Bruno Paiva, Pamplona, Spain
Rámon Lecumberri, Pamplona, Spain
• When to suspect AL amyloidosis during MGUS follow-up?
• New response criteria needed?
• Is there a role for MRD assessment?
• Are we curing AL amyloidosis in 2020?
• Amyloid deposition in organ transplant recipients?
Matthias Schmidt, Ulm, Germany
Ole Suhr, Umeå, Sweden
Violaine Plante-Bordeneuve, Créteil, France
David Adams, Paris, France
Esther González-López, Madrid, Spain
Joel Buxbaum, La Jolla, CA, USA
Juan Buades, Palma de Mallorca, Spain
• What is the real prevalence of wild type ATTR amyloidosis?
• What are the critical endpoints in ATTR polyneuropathy?
• Best treatment approach at lack of response to patisiran or inotersen?
• Is it time for combination therapy trials?
• What is the best approach to ATTR mutant carriers?
Clinical Trials in Progress in Systemic Amyloidosis